SCHEMBL3328822

SCHEMBL3328822

CCOC(=O)c1ccc2c(F)ccc(Br)c2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.49
▸ MAPT P10636 8/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ NPSR1 Q6W5P4 2/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ POLB P06746 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ MEN1 O00255 5/20 0.39
▸ KMT2A Q03164 5/20 0.39
▸ ALOX15 P16050 2/20 0.39
▸ GAA P10253 2/20 0.39
▸ GABRA2 P47869 2/20 0.39
▸ GABRB2 P47870 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ USP2 O75604 1/20 0.38
▸ EED O75530 1/20 0.38
▸ RBBP4 Q09028 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19584461 0.80 CYP1A2 (0.57) CYP1A2MAPTSMN1; SMN2NPSR1NPC1
SCHEMBL28433180 0.78 ALDH1A1 (0.54) CYP1A2MAPTSMN1; SMN2NPSR1NPC1
SCHEMBL3333925 0.78 KDM4E (0.43) MAPTRAB9AALDH1A1MEN1KMT2A
SCHEMBL1976720 0.77 CYP1A2 (0.50) CYP1A2MAPTSMN1; SMN2NPSR1NPC1
SCHEMBL1179778 0.76 CYP1A2 (0.61) CYP1A2MAPTSMN1; SMN2NPSR1NPC1
SCHEMBL31117393 0.75 CYP1A2 (0.59) CYP1A2MAPTSMN1; SMN2NPSR1NPC1
SCHEMBL18132220 0.75 CYP1A2 (0.59) CYP1A2MAPTSMN1; SMN2NPSR1NPC1
SCHEMBL29133108 0.74 CYP1A2 (0.57) CYP1A2MAPTSMN1; SMN2NPSR1NPC1
SCHEMBL1998568 0.73 CYP1A2 (0.49) CYP1A2MAPTSMN1; SMN2NPSR1NPC1
SCHEMBL38656054 0.73 CYP1A2 (0.56) CYP1A2MAPTSMN1; SMN2NPSR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144751-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-06-10 — — US disclosed
EP-2139888-A2 IMIDAZOÝ1,2-A¨PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2010-01-06 — — EP disclosed
WO-2008121687-A2 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2008-10-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144751-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS PIM1, PIM3, PIM2 CYP1A2 623/4885MAPT 3501/4885SMN1; SMN2 3736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback